BioCentury
ARTICLE | Clinical News

Benjorna: Phase III data

July 11, 2016 7:00 AM UTC

The double-blind, U.S. Phase III HLD-200-108 trial in 161 patients ages 6-12 with ADHD in a naturalistic setting showed that once-daily oral HLD-200 met the primary endpoint of improving ADHD-RS-IV to...